Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
about
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune ResistanceCXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targetingIdentifying and targeting tumor-initiating cells in the treatment of breast cancerHyaluronan, Inflammation, and Breast Cancer ProgressionThe CXCL8-CXCR1/2 pathways in cancerBlockade of Neutrophil's Chemokine Receptors CXCR1/2 Abrogate Liver Damage in Acute-on-Chronic Liver Failure.Tissue Factor promotes breast cancer stem cell activity in vitro.Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Comparison of stem/progenitor cell number and transcriptomic profile in the mammary tissue of dairy and beef breed heifers.An interactive network of elastase, secretases, and PAR-2 protein regulates CXCR1 receptor surface expression on neutrophils.The role of chemoattractant receptors in shaping the tumor microenvironment.The role of chemokines in breast cancer pathology and its possible use as therapeutic targetsInterleukin-8 in breast cancer progression.Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer.Wnt pathway activity in breast cancer sub-types and stem-like cellsHER2 and breast cancer stem cells: more than meets the eye.CXCR2 and its related ligands play a novel role in supporting the pluripotency and proliferation of human pluripotent stem cellsMolecular characterization and targeted therapeutic approaches in breast cancerIL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cellsPersistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer.Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy.Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectivenessBone marrow-derived mesenchymal stem cell-secreted IL-8 promotes the angiogenesis and growth of colorectal cancer.Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracilTargeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modellingHost Cxcr2-dependent regulation of mammary tumor growth and metastasisAn integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.Targeting the epigenetics of the DNA damage response in breast cancer.Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem CellsSubverting sterols: rerouting an oxysterol-signaling pathway to promote tumor growthCharacterization of a novel transgenic mouse tumor model for targeting HER2+ cancer stem cells.Harnessing the immune system for the treatment of breast cancer.Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis.Ubiquitin specific peptidase 21 regulates interleukin-8 expression, stem-cell like property of human renal cell carcinoma.The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans.Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications
P2860
Q26746986-A649ABCA-4652-4906-8467-9CFB72734697Q26849606-9B3CAE72-F562-491B-A6FF-E9CC54F0F3A5Q26851827-169641DC-0AE1-49CF-A8EE-B4D4E4A66E2DQ27006607-73D1F82B-5885-4547-9683-DD9FE8DE3C86Q28075994-2B4ED1F9-7BF4-4FC4-AE6E-4E98DA18B16DQ33593368-0234ADBD-C204-4AE2-8BD9-9BC5F5067652Q33688466-2684212C-372C-4E2D-8404-9AC26F861A7DQ33757061-16BC3EA4-3713-4D0D-8008-1624050EB383Q33786788-DDB64DA9-C337-4616-989C-D0582A9B915EQ33917475-4E90D9DA-2CAC-4457-A332-0975850A616BQ33947002-16187D35-940A-4887-A381-DE08AA701E0AQ33993124-7F2F9CBD-93AE-4A52-89E8-3501AD9376B3Q34069862-DA8B2865-3C94-4366-9EFB-6A02A604B70DQ34346108-CA4FAD99-9D5E-425A-8CCC-8BEE61DCFC1BQ34365904-875AE99D-9EB9-4E08-93AA-13931E791A56Q34826223-2E4170AA-5428-4F9C-BC07-2AE3AA2AB528Q35320325-CCA5F06A-E5B2-4FDB-B2EA-FE92DCBDE46EQ35324646-F043F4EF-B044-4ED1-A06F-511B787B839CQ35530143-07B369C8-5C08-44E8-ADFE-B8BD9D2C74CEQ35607293-7AE99765-9416-488A-986B-35742ECD4FE3Q35754295-0F9EB6A3-632E-4E23-B7E7-2E14BC0C308DQ35987267-7CA2EBDA-5B2A-4BC2-A8BC-18AD4082E37EQ36234132-2EE604A1-6B5E-441D-A253-732238C4DFA4Q36619033-0CD7D655-DAA3-40F5-A2CA-53420DB29493Q36649559-8CB9E9AF-7D0F-4ECE-B8C5-DCA42A15CC4FQ36685414-9A27FED6-E620-4D85-8E8D-60FD833EF5D9Q36767227-640AA7FA-62CF-42B3-8A6D-D562948643CCQ36771879-E1207D4C-7B3B-4A33-A508-AFDD197614A8Q36866453-C6EE8A67-0A89-41E2-BB88-FCD76B05B415Q37020846-7784D9E6-1837-4DC6-829B-58443D37EA54Q37125772-0A00F44E-845D-4D86-852C-7ECD99B70445Q37428738-1048531E-198B-45EB-B3DC-A0580DC329EBQ37476039-CE9B294D-652E-4740-9553-606D420A81C0Q37507350-F637B659-5091-41ED-83AD-3CEF3210B605Q37520425-04E18E8C-2939-4A78-A28C-713300B5FD19Q37595291-22F46A2A-DC58-4817-9613-81049827E3F3Q37662428-852312E5-BECE-467E-B18B-B0760918DACDQ37668209-DD909C7E-4EEA-43DD-AD93-FF363FC37311Q37690257-E2614254-0F89-4564-9F10-527981EEB416Q37735627-65C7F752-FFD3-4977-9F06-2CC063955860
P2860
Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting CXCR1/2 significantl ...... t and -independent mechanisms.
@en
type
label
Targeting CXCR1/2 significantl ...... t and -independent mechanisms.
@en
prefLabel
Targeting CXCR1/2 significantl ...... t and -independent mechanisms.
@en
P2093
P2860
P1476
Targeting CXCR1/2 significantl ...... t and -independent mechanisms.
@en
P2093
Amrita Shergill
Bruno M Simões
Gillian Farnie
Göran Landberg
Jagdeep K Singh
Nigel J Bundred
Robert B Clarke
P2860
P304
P356
10.1158/1078-0432.CCR-12-1063
P407
P50
P577
2012-11-13T00:00:00Z